annb0t
Top 20
SYDNEY, June 3, 2022 /PRNewswire/ --Â Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)
The data is the subject of a poster presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO), which is being held in Ch...
>>> Read more: KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
The data is the subject of a poster presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO), which is being held in Ch...
>>> Read more: KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
